Evidence map›Paper›PMID 26603155›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2016

Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.

Alan E Mast

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Targeted anticoagulant reversal, unintended consequences: lessons from andexanet alfa.European heart journal. Cardiovascular pharmacotherapy · 2026
    Article
  10. Review
  11. Advancements in CRISPR-basedFrontiers in genome editing · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Alan E MastFrom the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee; and Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee. alan.mast@bcw.edu.
Versiti Blood Center of Wisconsin · US

Funding

Tissue Factor Pathway Inhibitor Binding Proteins on EndoR01HL068835 · NHLBI · VERSITI WISCONSIN, INC. · PI Alan E Mast · 2002 to 2026
$9.7M
NHLBI NIH HHS R01 HL068835
6 · The paper itself

Abstract

Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits early phases of the procoagulant response. Alternatively spliced isoforms of TFPI are differentially expressed by endothelial cells and human platelets and plasma. The TFPIβ isoform localizes to the endothelium surface where it is a potent inhibitor of TF-factor VIIa complexes that initiate blood coagulation. The TFPIα isoform is present in platelets. TFPIα contains a stretch of 9 amino acids nearly identical to those found in the B-domain of factor V that are well conserved in mammals. These amino acids provide exosite binding to activated factor V, which allows for TFPIα to inhibit prothrombinase during the initiation phase of blood coagulation. Endogenous inhibition at this point in the coagulation cascade was only recently recognized and has provided a biochemical rationale to explain the pathophysiological mechanisms underlying several clinical disorders. These include the east Texas bleeding disorder that is caused by production of an altered form of factor V with high affinity for TFPI and a paradoxical procoagulant effect of heparins. In addition, these findings have led to ideas for pharmacological targeting of TFPI that may reduce bleeding in hemophilia patients.

Indexed as

Blood CoagulationAnimalsBlood Coagulation Disorders, InheritedCoagulantsFactor VIIaHumansLipoproteinsProtein BindingProtein ConformationProtein IsoformsThromboplastinCoagulantsFactor VIIalipoprotein-associated coagulation inhibitorLipoproteinsProtein IsoformsThromboplastinfactor Vfactor VIIhemophilia Alipoprotein-associated coagulation inhibitorthromboplastin

Identifiers

PMID26603155
PMCPMC4690769
OpenAlexW2486241607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.